The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1250 Weight Loss articles
Lasso, a food tech innovator, just launched Froobies and CronchClub—two snacks designed for GLP-1 users using proprietary SpinTech that weaves protein and fiber together. With clean ingredients, high macros, and craveable flavors, they address the nutritional demands of the GLP-1 era. Pre-order now and experience real snack innovation.
Sciwind Biosciences has secured a landmark $495 million commercialization deal with Pfizer China for Ecnoglutide, a next-generation cAMP-biased GLP-1 receptor agonist. Approved for type 2 diabetes in China, it shows 15.1% placebo-adjusted weight loss in trials. This partnership aims to address rising obesity rates amid national health initiatives.
Eris Lifesciences has partnered with Natco Pharma to bring semaglutide, a key GLP-1 receptor agonist, to the Indian market for Type 2 diabetes management. With CDSCO approval secured, the launch is set for March 2026. This move strengthens Eris's diabetes portfolio amid rising diabetes cases in India.
The UK Government has announced financial incentives for GPs to boost prescriptions of weight-loss injections Mounjaro and Wegovy on the NHS. Eight months into the mass rollout, not all practices are participating, prompting £25 million in funding for fairer access. Health Secretary Wes Streeting calls it a 'game changer' for obesity, but experts warn of workload risks.
Novo Nordisk faces an investor investigation by DJS Law Group over claims of misleading statements about its CagriSema weight loss drug trial. The phase 3 study failed to demonstrate non-inferiority against Eli Lilly's tirzepatide after 84 weeks, triggering a sharp 15%+ premarket stock plunge on February 23, 2026. Investors affected by the drop may have rights under securities laws.
Shares of Viking Therapeutics surged approximately 12% on Monday following a clinical setback for Novo Nordisk's next-generation obesity drug CagriSema, which underperformed Eli Lilly's Tirzepatide in a pivotal Phase 3 trial. This shift highlights intensifying competition in the GLP-1 obesity market. Investors are eyeing Viking's VK2735 as a promising contender.
In 2024, the US pharmaceutical market crowned Keytruda (Merck & Co.) as the top-selling drug with $17.87 billion in revenue, according to Statista's 'Top pharmaceutical drugs' report. Oncology treatments like Keytruda lead, followed by diabetes heavyweights Ozempic and Mounjaro. This ranking underscores the shift toward biologics for cancer, diabetes, and autoimmune diseases.
In a pivotal head-to-head trial, Novo Nordisk's next-generation obesity drug CagriSema delivered 23% body weight reduction over 84 weeks, missing the mark against Eli Lilly's tirzepatide at 25.5%. This setback highlights the intense competition in the weight-loss market. Novo shares dropped 11%, while Lilly's rose 4%.
Hims & Hers is acquiring Australian telehealth firm Eucalyptus for $1.15 billion to fuel global growth amid U.S. regulatory scrutiny over compounded GLP-1s. Experts call it a smart diversification move that complements weight loss and wellness services. This expansion could reshape access to personalized care worldwide.
